METHODS: We conducted a territorywide, retrospective cohort study in NA-treated CHB
patients between 2000 and 2018 from the electronic healthcare data repository in Hong …

Background & Aims Treatment for hepatitis B virus infection reduces the risk of
hepatocellular carcinoma (HCC). However, the long-term protective effects for subgroups of …

Importance Antiviral therapy cannot erase hepatocellular carcinoma (HCC) risk in patients
with chronic hepatitis B, and it is not indicated for most hepatitis B virus (HBV) carriers …

Background Patients with chronic hepatitis B (CHB) need long‐term antiviral treatment with
nucleos (t) ide analogues (NA). Animal studies suggest that some NA may increase cancer …

Summary Background North American data are lacking on the effect of nucleos (t) ide
analogues (NA) in preventing chronic hepatitis B (CHB)‐related hepatocellular carcinoma …

Background In patients with chronic hepatitis B (CHB)‐related hepatocellular carcinoma
(HCC), high viral load was associated with tumour recurrence and deaths. Aims To …

BACKGROUND Hepatocellular carcinoma (HCC) is a major complication of hepatitis B virus
(HBV) infection. This study investigated the association between nucleos (t) ide analogue …

METHODS: Nationwide data covering the HBV-infected population in the Republic of Korea
from 2010 to 2011 were analyzed. Patients who had been taking Aspirin for≥ 3 years were …

Background It is generally stated that oral antiviral therapy in patients with chronic hepatitis
B (CHB) decreases the risk of developing hepatocellular carcinoma (HCC). Although oral …

Patients with a chronic hepatitis B virus (HBV) infection who are treated with nucleos (t) ide
analogues (NAs) are still at risk for hepatocellular carcinoma (HCC), and it has been …